Remote Enrollment Initiated in MGH Study Assessing Mood Symptoms Across Infertility Treatment
We are pleased to announce the recent launch of an exciting new research initiative that is being conducted by the Massachusetts General Hospital Center for Women’s Mental Health. The Symptom Tracking in Assisted Reproductive Technologies study (START study) will focus on understanding the risk factors for depressive relapse in women undergoing infertility treatments. There has been a growing request in our clinical work to address the needs of women undergoing infertility treatments. It is our hope that such a study will provide important information on the course and risk of depression in women undergoing fertility treatment and thus inform clinical care.
Omega-3 Fatty Acids and Perinatal Depression: Maybe or Maybe Not
The omega-3 fatty acids, including eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA), have a broad range of health benefits and may be beneficial for the treatment of mood disorders. Because during pregnancy omega-3 fatty acids are diverted to the developing fetus, some women may develop a deficiency of omega-3 fatty acids during pregnancy. Previous studies have shown that pregnant women with lower levels of DHA may be more vulnerable to depressive symptoms. Several small studies have attempted to use omega-3 fatty acids to treat perinatal depression but have yielded inconsistent findings.
Mediterranean Diet Benefits Perimenopausal Women with Hot Flashes
In a large study from Australia, researchers found that menopausal women who ate diets high in fruit, certain vegetables, pasta and red wine were 20% less likely to have hot flashes and night sweats.
Research from the CWMH: Duloxetine for Menopausal Symptoms
A substantial proportion of women transitioning into menopause experience a new onset or recurrence of depressive symptoms. A new study from the Center for Women’s Mental Health indicates that duloxetine (Cymbalta) is effective for the treatment of depression and may also have a beneficial effect on vasomotor symptoms (hot flashes and night sweats).
SSRI Exposure During Pregnancy Does Not Appear to Affect Infant Growth
Some studies have shown an association between in utero exposure to antidepressants and various pregnancy outcomes, including preterm delivery, low birth weight, and lower Apgar scores; however, these outcomes have also been observed in infants born to depressed mothers who are not taking medication. Thus, it has been difficult to determine if there is a causal relationship between antidepressant exposure and these negative pregnancy outcomes or if untreated maternal depression is itself responsible for these negative outcomes.
Gabapentin (Neurontin) and Pregnancy
Despite the fact that gabapentin (Neurontin) is now used in a wide variety of clinical settings -- for epilepsy, pain management, anxiety, sleep disturbance – there is relatively little information regarding its reproductive safety. A prospective study from researchers at the Motherisk program reports on the outcomes of 223 pregnancies exposed to gabapentin and 223 unexposed pregnancies.